A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study of the Long-Term Efficacy, Tolerability and Safety of Agomelatine 25 and 50 mg in the Prevention of Relapse of Major Depressive Disorder (MDD) Following Open-Label Treatment of 16-24 Weeks

Trial Profile

A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study of the Long-Term Efficacy, Tolerability and Safety of Agomelatine 25 and 50 mg in the Prevention of Relapse of Major Depressive Disorder (MDD) Following Open-Label Treatment of 16-24 Weeks

Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2012

At a glance

  • Drugs Agomelatine (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 18 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 May 2010 Actual patient number (644) added as reported by ClinicalTrials.gov.
    • 01 Apr 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top